West Pharmaceutical Services is experiencing a reacceleration in growth, with revenue up 13.8% in 2026Q2, driven by high-value components and GLP-1 elastomers. Gross margin expanded to 37.7% as mix shifts toward high-value products, and operating leverage is e...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 13.8% in 2026Q2, with gross margin expanding to 37.7% from 35.7% a year earlier, reflecting a favorable mix shift toward high-value products.
West Pharmaceutical Services has a consistent track record of exceeding earnings expectations, indicating strong financial performance.
The company is a leading global manufacturer of advanced containment and delivery systems for injectable medicines, positioning it as a trusted industry player.
West specializes in designing and producing high-quality, technologically advanced packaging and delivery systems for pharmaceuticals, driving growth in the sector.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 23, 2026 | $2.37+13.9% vs $2.08 | $872M+3.8% vs $840M |
Q2 2026 Apr 23, 2026 | $2.13+26.8% vs $1.68 | $845M+8.3% vs $780M |
Q1 2026 Feb 12, 2026 | $2.04+11.5% vs $1.83 | $805M+1.3% vs $795M |
Q4 2025 Oct 23, 2025 | $1.96+16.7% vs $1.68 | $804M+2.4% vs $786M |
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
HB Wealth Management LLC lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 28.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,709 shares of the medical instruments supplier's stock after selling 1,858 shares during the quarter.
West Pharmaceutical Services (NYSE: WST - Get Free Report) and Acutus Medical (NASDAQ: AFIB - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends. Volatility and Risk West Pharmaceutical Services has
Benchmark WST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for West Pharmaceutical Services, Inc. (WST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $375.97 | $26.46B | 55.29 | 6.26% | 16.06% | 16.85% | 0.22% | |
| $124.74 | $7.96B | 21.21 | 5.42% | 9.22% | 13.34% | — | |
| $209.90 | $10.05B | 636.06 | 2.49% | -0.63% | -0.78% | — | |
| $14.76 | $9.98B | -18.92 | -3.41% | -8.81% | -10.34% | — | |
| $42.80 | $19.79B | 17.98 | 56.61% | 4.71% | 9.44% | — | |
| $42.15 | $6.21B | 12.29 | -0.61% | 9.43% | 48.39% | — |
West Pharmaceutical Services, Inc. (WST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
West Pharmaceutical Services, Inc. (WST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 23, 2026·SEC
Jul 14, 2026·SEC
Jun 1, 2026·SEC
Get notified when WST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
West Pharmaceutical Services, Inc. (WST) stock FAQ — growth, dividends, profitability & financials explained
West Pharmaceutical Services, Inc. (WST) reported $3.33B in revenue for fiscal year 2025. This represents a 625% increase from $458.8M in 1996.
West Pharmaceutical Services, Inc. (WST) grew revenue by 6.3% over the past year. This is steady growth.
Yes, West Pharmaceutical Services, Inc. (WST) is profitable, generating $564.9M in net income for fiscal year 2025 (16.1% net margin).
Yes, West Pharmaceutical Services, Inc. (WST) pays a dividend with a yield of 0.22%. This makes it attractive for income-focused investors.
West Pharmaceutical Services, Inc. (WST) has a return on equity (ROE) of 16.9%. This is reasonable for most industries.
West Pharmaceutical Services, Inc. (WST) generated $436.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
